| Literature DB >> 33599901 |
Malgorzata Zalewska-Adamiec1, Jolanta Malyszko2, Ewelina Grodzka1, Lukasz Kuzma1, Slawomir Dobrzycki1, Hanna Bachorzewska-Gajewska1,3.
Abstract
BACKGROUND: Myocardial infarction with nonobstructive coronary arteries (MINOCA) constitutes about 10% of the cases of acute coronary syndromes (ACS). It is a working diagnosis and requires further diagnostics to determine the cause of ACS.Entities:
Keywords: Chronic kidney disease; Glomerular filtration; MINOCA; Myocardial infarction; Myocarditis; Takotsubo
Mesh:
Year: 2021 PMID: 33599901 PMCID: PMC8599341 DOI: 10.1007/s11255-021-02794-x
Source DB: PubMed Journal: Int Urol Nephrol ISSN: 0301-1623 Impact factor: 2.370
Fig. 1The distribution of eGFR (mL/min/1.73 m2) in MINOCA (N = 178)
Clinical and demographic characteristics—comparison of the groups of patients with MINOCA (N = 178)
| MINOCA | Group 1 | Group 2 | ||
|---|---|---|---|---|
| Age (years) | 64.67 (16.31) | 77.40 (10.52) | 59.27 (15.39) | |
| Female sex (%) | 101 56.74% | 39 73.58% | 62 49.60% | |
| Body mass index (BMI) kg/m2 | 27.29 (5.06) | 26.62 (4.21) | 27.58 (5.84) | 0.297 |
| History of malignancy (%) | 18 10.11% | 7 13.21% | 11 8.80% | 0.372 |
| History of hypertension (%) | 125 70.22% | 49 92.45% | 76 60.80% | |
| Hyperlipidemia (%) | 106 59.55% | 31 58.49% | 75 60.00% | 0.851 |
| Smoking (%) | 63 35.39% | 12 22.64% | 51 40.80% | |
| Family history of coronary artery disease (%) | 31 17.42% | 6 11.32% | 25 20.00% | 0.162 |
| Diabetes mellitus (%) | 29 16.29% | 17 32.08% | 12 9.60% | |
| Anxiety/depression (%) | 7 3.93% | 1 1.89% | 6 4.80% | 0.361 |
| Thyroid disorders (%) | 29 16.29% | 8 15.09% | 21 16.80% | 0.777 |
| Asthma, COPD (%) | 21 11.80% | 8 15.09% | 13 10.40% | 0.375 |
| Previous MI (%) | 29 16.29% | 10 18.87% | 19 15.20% | 0.544 |
Significant p values are indicated in bold
COPD chronic obstructive pulmonary disease, MI myocardial infarction
Diagnostic tests (echocardiography, coronarography, ECG)—comparison of the groups of patients with MINOCA (N = 178)
| MINOCA | Group 1 | Group 2 | ||
|---|---|---|---|---|
| LVEF (%) | 46.19 (12.42) | 42.84 (13.95) | 47.54 (11.60) | |
| No atherosclerotic changes in coronary arteries (%) | 45 25.28% | 5 9.43% | 40 32.00% | |
| Insignificant stenoses < 50% (%) | 133 74.72% | 48 90.57% | 85 68.00% | |
| Insignificant stenoses < 30% (%) | 35 19.66% | 7 13.21% | 28 22.40% | 0.158 |
| Insignificant stenoses ≥ 30% but < 50% (%) | 98 55.06% | 41 77.36% | 57 45.60% | |
| ECG–ST-segment elevation (%) | 70 39.33% | 21 39.62% | 49 39.20% | 0.958 |
| ECG–ST-segment depression (%) | 26 14.61% | 8 15.09% | 18 14.40% | 0.905 |
| Negative T waves (%) | 72 40.45% | 24 45.28% | 48 38.40% | 0.392 |
| QTc on admission (ms) | 459.61 (36.51) | 474.21 (41.99) | 453.36 (32.30) | |
| QTc after a few days (ms) | 458.90 (40.26) | 476.85 (40.87) | 451.15 (37.82) |
Significant p values are indicated in bold
ECG electrocardiogram, LVEF left ventricular ejection fraction
Laboratory parameters—comparison of the groups of patients with MINOCA (N = 178)
| MINOCA | Group 1 | Group 2 | ||
|---|---|---|---|---|
| Hemoglobin (mg/dl) | 13.63 (1.74) | 13.29 (1.88) | 13.77 (1.68) | 0.090 |
| Erytrocytes(× 106/μl) | 4.49 (0.59) | 4.48 (0.63) | 4.50 (0.58) | 0.835 |
| Hematocrit (%) | 40.13 (4.65) | 39.72 (5.36) | 40.31 (4.35) | 0.446 |
| Leukocytes (× 103/μl) | 9.48 (4.36) | 10.28 (5.03) | 9.15 (4.04) | 0.113 |
| Thrombocytes ( | 246.20 (98.40) | 235.70 (108.98) | 250.67 (94.09) | 0.355 |
| Glucose on admission (mg/dl) | 119.80 (43.33) | 137.50 (60.71) | 112.33 (31.15) | |
| HbA1C (%) | 5.93 (0.86) | 6.28 (1.16) | 5.78 (0.65) | |
| Creatinine (mg/dl) | 0.99 (0.42) | 1.40 (0.56) | 0.82 (0.15) | – |
| eGFR MDRD (m/min/1.72 m2) | 73.84 (25.61) | 43.04 (11.29) | 86.89 (17.63) | – |
| eGFR CKD-EPI (m/min/1.72 m2) | 79.27 (30.66) | 42.83 (11.83) | 94.72 (21.96) | – |
| CK (IU/L) | 373.50 (670.42) | 288.11 (412.69) | 409.76 (754.54) | 0.271 |
| CKMB (IU/L) | 75.66 (78.59) | 59.98 (39.56) | 82.42 (84.78) | 0.067 |
| Troponin (significant increase) (%) | 100% | 100% | 100% | – |
| Troponin–mean concentration (ng/mL) | 5829.70 (8555.71) | 4977.59 (7448.31) | 6184.12 (9013.26) | 0.396 |
| Total cholesterol (mg/dl) | 178.10 (44.40) | 162.48 (39.73) | 184.70 (44.96) | |
| LDL (mg/dl) | 108.20 (39.36) | 94.08 (36.54) | 114.20 (39.30) | |
| HDL (mg/dl) | 48.58 (15.85) | 44.04 (13.80) | 50.53 (16.39) | |
| Triglycerides (mg/dl) | 114.10 (69.79) | 128.71 (78.12) | 107.88 (65.58) | 0.072 |
| CRP (mg/l) | 51.38 (85.39) | 58.92 (80.16) | 48.68 (87.89) | 0.552 |
| Fibrinogen (mg/l) | 431.16 (142.16) | 451.30 (151.66) | 422.55 (138.23) | 0.220 |
| BNP (pg/mL) | 597.03 (801.22) | 1091.36 (1142.30) | 394.80 (493.96) | |
| Hospitalization time (days) | 4.31 (3.11) | 4.02 (2.31) | 4.43 (3.40) | 0.419 |
Significant p values are indicated in bold
BNP peptyd natriuretyczny typu B, eGFR estimated glomerular filtration rate, CK creatine kinase, LDL low-density lipoprotein, HDL high-density lipoprotein, CRP c-reactive protein
Clinical course and complications—comparison of the groups of patients with MINOCA (N = 178)
| MINOCA | Group 1 | Group 2 | ||
|---|---|---|---|---|
| RRs on admission | 134.88 (25.11) | 135.94 (25.31) | 134.43 (25.22) | 0.715 |
| RRr on admission | 77.42 (13.57) | 75.64 (14.34) | 78.17 (13.27) | 0.258 |
| HR on admission | 80.04 (19.58) | 85.58 (24.56) | 77.69 (16.69) | |
| HR after a few days | 70.01 (15.35) | 73.81 (18.70) | 68.40 (13.53) | |
| Retrosternal chest pain (%) | 161 90.45% | 46 86.79% | 115 92.00% | 0.631 |
| Dyspnea (%) | 13 7.30% | 4 7.55% | 9 7.20% | 0.934 |
| Cardiac arrest, pulmonary oedema, cardiogenic shock (%) | 12 6.74% | 7 13.21% | 5 4.00% | |
| Pneumonia (%) | 20 11.24% | 12 22.64% | 8 6.40% | |
| Urinary tract infection (%) | 9 5.06% | 4 7.55% | 5 4.00% | 0.323 |
| Rhythm disturbances (%) | 26 14.67% | 10 18.87% | 16 12.80% | 0.294 |
| Hospitalization time (days) | 4.31 (3.11) | 4.02 (2.31) | 4.43 (3.40) | 0.419 |
Significant p values are indicated in bold
RR blood pressure, HR heart rate
Pharmacological treatment at discharge—comparison of the groups of patients with MINOCA (N = 178)
| MINOCA | Group 1 | Group 2 | ||
|---|---|---|---|---|
| Clopidogrel | 108 60.67% | 36 67.92% | 72 57.60% | 0.197 |
| Aspirin | 158 88.76% | 49 92.45% | 109 87.20% | 0.310 |
| ACEI/ARB | 143 80.34% | 44 83.02% | 99 79.20% | 0.557 |
| β-blockers | 151 84.83% | 43 81.13% | 108 86.40% | 0.370 |
| Statin | 139 78.09% | 42 79.25% | 97 77.60% | 0.807 |
ACEI angiotensyn converting enzyme inhibitor, ARB angiotensin II receptor blocker
Fig. 2The distribution of final diagnosis in total MINOCA group (N = 178)
Fig. 3The distribution of final diagnosis in 2 MINOCA groups (N = 178)
Comparison of mortality rate between the two MINOCA groups (N = 178)
| MINOCA | Group 1 | Group 2 | ||
|---|---|---|---|---|
| In hospital (%) | 5 2.81% | 4 7.55% | 1 0.80% | |
| 1 months (%) | 12 6.74% | 9 16.98% | 3 2.40% | |
| 6 months (%) | 21 11.80% | 12 22.64% | 9 7.20% | |
| 1 year (%) | 23 12.92% | 14 26.42% | 9 7.20% | |
| 3 year (%) | 30 16.85% | 18 33.96% | 12 9.6% |
Significant p values are indicated in bold
Fig. 4The Kaplan–Meier curve of survival probability of patients with MINOCA (N = 178)
Distribution of deaths in both MINOCA groups depending on the final diagnosis (N = 178)
| MINOCA | Group 1 | Group 2 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Deaths ( | Deaths ( | Deaths ( | ||||||||
| % | % | % | ||||||||
| MINOCA | 69 | 12 | 17.4 | 23 | 6 | 26.1 | 46 | 6 | 13.0 | 0.175 |
| Takotsubo | 69 | 15 | 21.7 | 24 | 10 | 41.7 | 45 | 5 | 11.1 | |
| Myocarditis | 25 | 1 | 4.0 | 1 | 0 | 0.0 | 24 | 1 | 4.2 | – |
| Type 2 MI | 15 | 2 | 13.3 | 5 | 2 | 40.0 | 10 | 0 | 0.0 | – |
Significant p value is indicated in bold
Univariate and multivariate regression analysis of risk factors of death in patients with MINOCA (N = 178)
| Predictor | Univariable | Multivariable | ||||
|---|---|---|---|---|---|---|
| Odd ratio | 95% Cl | Odds ratio | 95% Cl | |||
| Female sex | 0.614 | 0.279–1.350 | 0.2245 | |||
| Age | 1.049 | 1.017–1.082 | 0.0028 | |||
| BMI < 20 | 0.949 | 0.870 | 0.2365 | |||
| eGFR CKD-EPI | 0.983 | 0.969 | 0.0145 | |||
| Hypertension | 1.861 | 0.713 | 0.2042 | |||
| Hypercholesterolemia | 0.383 | 0.171 | 0.0192 | |||
| Diabetes mellitus | 1.822 | 0.695 | 0.2222 | |||
| ST elevation | 3.539 | 1.531 | 0.0031 | |||
| LVEF < 40% | 0.929 | 0.898 | 0.0000 | |||
| Hemoglobin | 0.655 | 0.512 | 0.0007 | |||
| LEU | 1.130 | 1.043 | 0.0027 | |||
| Troponin | 1.000 | 1.000 | 0.0117 | |||
| LDL | 0.980 | 0.968 | 0.0018 | |||
| BNP | 1.001 | 1.000 | 0.0044 | |||
| HbA1c | 1.453 | 0.957 | 0.0797 | |||
| Creatinin | 8.162 | 2.606 | 0.0003 | |||
Significant p values are indicated in bold
Cl confidence interval